ATTRACTNCT07732309
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Sep 1, 2026 to Sep 26, 2026
- Site details revised at 22 of 22 sites
- Notable Eligibility criteria shortened, about 18 words
- Site details revised at 4 of 22 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety and TolerabilitySafety and Tolerability
Timeframe: 48 weeks
Arms and interventions
ATG-201Experimental
This is a phase I, open-label, first-in-human clinical trial to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of ATG-201 in participants with autoimmune diseases. The study will be conducted in 2 parts: Dose Escalation (Part I) and Dose Expansion (Part II). Part I (Dose Escalation) A total of 9 dose levels is preset In Part II (Dose Expansion), the OBD(s) will be further explored and evaluated
Drugs: ATG-201
Sites
22 sites in 1 country